BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax is a first-in-class, potent, oral B-cell lymphoma (BCL-2) inhibitor that is approved for treatment of chronic lymphocytic leukemia (CLL) and adult AML 7 and is currently under development for several other hematological malignancies including ALL, multiple myeloma (MM), mantle cell lymphoma (MCL) and pediatric AML 8.